Sanders Morris Harris LLC Acquires 1,830 Shares of argenex SE $ARGX

Sanders Morris Harris LLC acquired a new stake in argenex SE (NASDAQ:ARGX) in the third quarter, HoldingsChannel.com reports. The firm acquired 1,830 shares of the company’s stock, valued at approximately $1,755,000.

Several other institutional investors have also recently added to or reduced their stakes in ARGX. Whipplewood Advisors LLC purchased a new position in argenex during the first quarter worth about $28,000. Eastern Bank acquired a new stake in argenex in the 2nd quarter worth about $32,000. Axiom Investment Management LLC acquired a new stake in argenex in the 1st quarter worth about $50,000. WPG Advisers LLC grew its holdings in argenex by 17.8% in the 1st quarter. WPG Advisers LLC now owns 86 shares of the company’s stock valued at $63,000 after buying an additional 13 shares during the period. Finally, Fifth Third Bancorp grew its holdings in argenex by 616.7% in the 1st quarter. Fifth Third Bancorp now owns 172 shares of the company’s stock valued at $126,000 after buying an additional 148 shares during the period. 60.32% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the stock. Jefferies Financial Group reaffirmed a “buy” rating on shares of argenex in a research note on Monday, September 14th. Citizens Jmp raised their target price on shares of argenex from $932.00 to $1,200.00 and gave the stock a “market outperform” rating in a research report on Tuesday, August 18th. Wall Street Zen cut shares of argenex from a “buy” rating to a “hold” rating in a research report on Saturday, September 19th. Wells Fargo & Company boosted their target price on shares of argenex from $1,355.00 to $1,356.00 and gave the company an “overweight” rating in a report on Wednesday. Finally, UBS Group raised shares of argenex from a “neutral” rating to a “buy” rating and upped their price target for the stock from $960.00 to $1,400.00 in a research report on Wednesday, August 26th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $1,151.95.

argenex Stock Performance

argenex stock traded up $15.66 during midday trading on Wednesday, reaching $818.30. The stock had a trading volume of 464,115 shares, compared to its average volume of 346,021. argenex SE has a twelve month low of $661.85 and a twelve month high of $1,072.75. The stock has a market capitalization of $51.19 billion, a PE ratio of 31.42, a price-to-earnings-growth ratio of 0.85 and a beta of 0.44. The stock’s 50-day simple moving average is $958.72 and its 200 day simple moving average is $879.19.

argenex (NASDAQ:ARGX) last posted its quarterly earnings results on Tuesday, July 21st. The company reported $7.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.86 by $1.46. The firm had revenue of $1.54 billion during the quarter, compared to the consensus estimate of $1.45 billion. argenex had a return on equity of 43.59% and a net margin of 32.19%. Equities analysts predict that argenex SE will post 28.71 earnings per share for the current fiscal year.

argenex Profile

argenx SE (NASDAQ:ARGX) is a global immunology company focused on developing and commercializing therapies for patients with severe autoimmune diseases. The company combines antibody engineering technologies with disease biology to discover medicines that target the underlying mechanisms of immune-mediated disorders.

argenx’s leading product is efgartigimod, marketed as Vyvgart and Vyvgart Hytrulo in the United States. The therapies are designed to reduce disease-causing immunoglobulin G (IgG) antibodies by targeting the neonatal Fc receptor (FcRn).